Rocket Lab Completes Spacecraft Commissioning for ESCAPADE Mars Mission Rocket Lab Completes Spacecraft Commissioning for ESCAPADE Mars Mission LONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rocket Lab USA, a wholly owned subsidiary of Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced the successful completion of commissioning for the twin Rocket Lab-built satellites for the University of California Berkele ...

Core Insights - SoundHound AI, Inc. reported a record number of enterprise deals in Q4 2025, positioning itself as a leading partner for businesses amid the disruption of traditional software and services [4][6] - The company experienced significant growth in revenue and key profit metrics, driven by increased demand for enterprise-grade AI solutions [4][6] Financial Highlights - Q4 2025 revenue reached $55.1 million, a 59% increase year-over-year [7][15] - Full year 2025 revenue was $168.9 million, marking a 99% increase year-over-year [7][16] - Q4 GAAP gross margin was 47.9%, while non-GAAP gross margin was 60.5% [7][15] - Full year GAAP gross margin was 42.4%, and non-GAAP gross margin was 58.0% [7][16] - Q4 GAAP net income was $40.1 million, with a non-GAAP net loss of $7.3 million [7][15] - Full year GAAP net loss was $14.0 million, and non-GAAP net loss was $53.9 million [7][16] Business Developments - The company signed a new prominent OEM in Japan with a seven-digit unit commitment and closed a deal with a new Korean OEM [8] - SoundHound expanded its partnerships with various automotive manufacturers, including a major American automaker and several global brands [13] - The company enhanced its voice commerce capabilities by adding new merchants and expanding its ecosystem [13] Liquidity and Cash Flow - As of December 31, 2025, SoundHound had total cash and cash equivalents of $248 million with no debt [18] - The net cash used in operating activities for the year was $98.2 million, while net cash provided by financing activities was $208.1 million [19] Business Outlook - The revenue outlook for full year 2026 is projected to be between $225 million and $260 million [20]

Fourth quarter revenue growth of 9% with organic growth of 5% Accelerating AMS/DRS fourth quarter organic growth to 22%Record 2025 cash generation with cash from operations of $640M and free cash flow of $436M Reduced net debt leverage to 2.7x Adjusted EBITDA RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced fourth-quarter and full-year 2 ...

AUSTIN, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder and Chief Executive Officer, will present at The Citizens Technology Conference in San Francisco. Event Details: Date: Tuesday, March 3, 2026Time: 11 AM PT / 2 PM ETWebcast: A live audio webcast of the presentation will be available on the Ethos Investor Relations website at investors.ethos.com. The presentatio ...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan (“NOL Plan”) designed to help preserve and protect Seer’s valuable income tax net operating loss carryforwards and other tax assets (“NOLs”). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subjec ...

LONG BEACH, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has completed the acquisition of Optical Support, Inc. (OSI), a leader in the design, engineering, and manufacturing of custom, high-precision optical and optomechanical instruments. OSI’s advanced lenses and optomechanical systems are critical enablers for national security and commercial satellites, and are key ...

Cash and stock transaction combines two complementary trusted and globally recognized financial technology infrastructure providers to better serve banking and retail customers Positioned to accelerate Brink’s growth in high-margin AMS and DRS businesses by expanding into large, under-penetrated addressable markets Expected to deliver at least 35% accretion to EPS, while generating strong cash flow with an estimated $200 million in annual run-rate cost synergies RICHMOND, Va. and ATLANTA, Feb. 26, 2026 (GLO ...

NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 10, 2026 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertensi ...

Achieves fifth consecutive quarter of GAAP profitability Full year 2025 GAAP EPS of $0.53, up $2.48 year-over-year Full year 2025 Adjusted EPS of $1.36, reflecting 89% growth Meets or outperforms each fourth quarter and full year guidance metric SAN MATEO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Oportun Financial Corporation (Nasdaq: OPRT) (“Oportun”, or the "Company") reported financial results today for the fourth quarter and full year ended December 31, 2025. “We finished 2025 with another solid perf ...

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new p ...